12th February 2025 – Cambridge, UK – Cresset, a leading provider of integrated in silico solutions for small molecule drug discovery announces the release of its Flare platform V10, bringing enhanced scientific features for both computational and medical chemists.

The latest release includes significantly enhanced Free Energy Perturbation (FEP) calculations with the inclusion of Absolute FEP, Protein-protein docking, and Protein-Ligand Interaction Fingerprints (PLIF).

Science, research and innovation are core disciplines that will undoubtedly help the human race address many of the key challenges it faces. Whether it is dealing with climate change, ending world hunger or living healthier and longer lives, we need to create environments that will enable scientists and researchers to make ground-breaking discoveries to be made. That means building a support network to work alongside them made up of individuals with other skills and disciplines.

PrecisionLife has been awarded a €2.5m non-dilutive grant by the European Innovation Council (EIC) for its TRANSCEND project, to more rapidly and accurately triage and treat patients with endometriosis. The project is based on PrecisionLife’s unique insights into the biological mechanisms underpinning this complex chronic disease. It will develop and clinically validate a rapid and non-invasive precision medicine test to evaluate a patient’s risk of endometriosis and the mechanisms underpinning their disease.

AMSBIO announces a new range of ready-to-use Human induced Pluripotent Stem Cell (hiPSC) -derived cardiomyocytes, hepatocytes, and neurons. Supplied fully differentiated and available in high-purity formats, these ready-to-use cells help accelerate research by streamlining lab workflows, eliminating the need for in-house differentiation and minimizing preparation time.

This Aon’s Life Sciences webinar offered an insightful discussion on managing risk in Clinical Trials, focusing on insurance, regulatory requirements, and creating operational efficiencies. Attendees learned about the latest trends in risk transfer, hybrid programs, and how technology is streamlining processes to support clinical trial success.

The Webinar also covered areas including:

Primary Stakeholders and exposures, including contractual and service agreements.

EU directive and CTIS database, the transparency rules, and the impact on insurance

• Appointment of leading financial executive supports continued commercial development
• Current CFO at Telesis Bio, former CFO of BioLegend Inc.

Cambridge, UK, 18 February 2025: Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ system, today announced the appointment of William J. Kullback to its Board of Directors as a Non-Executive Director (NED).

After a period of significant volatility, a more optimistic outlook is on the horizon for the life sciences industry in 2025. With the right level of preparedness, firms can take full advantage of the potential opportunities the new year will bring.